Thermo Fisher Scientific Inc. Q3 2026 Earnings Call Summary

Thermo Fisher (TMO) reported Q3 2026 revenue growth of 9% to $12.14B, adjusted EPS up 15% to $6.68. Adjusted operating income rose 15% to $2.97B. The company highlighted strong performance across pharma, biotech, and diagnostics, driven by new product launches and strategic initiatives. Thermo Fisher also discussed progress in AI integration and capital deployment, including the Clario acquisition and divestiture of the microbiology business.

Thermo Fisher Scientific (TMO) reported Q3 2026 earnings with adjusted EPS of $6.68 (vs $6.40 expected) and revenue of $12.14B (vs $11.95B expected). Organic growth was 6%, leading to raised full-year guidance. The stock initially fell 2.5% premarket but recovered to +1.63% intraday. Management expects normal growth by late 2027 or early 2028.

Thermo Fisher Scientific (TMO) reported Q3 revenue growth across most segments, with Life Sciences up 5%, Analytical Instruments up 6%, and Lab Products up 15%. Specialty Diagnostics saw a 6% revenue decline. Adjusted operating margins improved in all segments. The company introduced AI-enabled products and raised its 2026 revenue and EPS guidance to $47.7B-$48.2B and $25.13-$25.43, respectively. It also completed the divestiture of its microbiology business and repaid $1.1B in senior notes.

Thermo Fisher Scientific (TMO) reported Q3 2026 earnings of $6.68 per share, up 15% YoY, and revenues of $12.14B, up 9% YoY, both beating estimates. Despite strong results, TMO stock fell 4.1% in pre-market trading. The company saw growth in most segments except Specialty Diagnostics, which declined 6.5%. Adjusted operating margin widened to 24.5%. TMO also announced strategic partnerships and new product launches. The company plans to provide updated full-year guidance on Oct. 21.

Thermo Fisher Scientific (TMO) reported Q3 2026 earnings of $6.68 per share, beating estimates of $6.40. Revenue grew 9% YoY to $12.14B, exceeding expectations of $11.95B. Operating income rose 15% to $2.97B, with margins improving to 24.5%. Laboratory products and services drove growth, while specialty diagnostics declined. Updated 2026 guidance will be provided.

Thermo Fisher Scientific reported Q3 revenue of $12.14B, up 9% YoY, with adjusted EPS rising 15% to $6.68. Organic growth was 6%, and margins improved. The company launched new products, partnered with Mayo Clinic, and opened new facilities. GAAP EPS increased 9% to $4.64. Shares fell 2% premarket.